LeMaitre Vascular (NASDAQ:LMAT) Issues FY 2026 Earnings Guidance

Key Points

• FY 2026 guidance: LeMaitre issued EPS guidance of 2.930–3.080 (consensus 2.900) and revenue guidance of $277.0M–$283.0M, with Q2 EPS guided at 0.790–0.840.
• Analyst view vs. share price: The consensus rating is a Moderate Buy with an average target of $105.80, while the stock was trading around $112.32, above the average target.
• Dividend raised: The company increased its quarterly dividend to $0.25 ($1.00 annualized), a yield of about 0.9% and a payout ratio near 39.8%.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 2.930-3.080 for the period, compared to the consensus earnings per share estimate of 2.900. The company issued revenue guidance of $277.0 million-$283.0 million, compared to the consensus revenue estimate of $279.5 million. LeMaitre Vascular also updated its Q2 2026 guidance to 0.790-0.840 EPS.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Freedom Capital upgraded LeMaitre Vascular to a "hold" rating in a research report on Tuesday, March 31st. Roth Mkm reaffirmed a "buy" rating and issued a $117.00 price target (up from $108.00) on shares of LeMaitre Vascular in a research note on Thursday, February 26th. Wall Street Zen raised shares of LeMaitre Vascular from a "hold" rating to a "buy" rating in a research report on Saturday, February 21st. Wells Fargo & Company increased their price objective on shares of LeMaitre Vascular from $87.00 to $94.00 and gave the stock an "equal weight" rating in a research note on Thursday, February 26th. Finally, Weiss Ratings raised shares of LeMaitre Vascular from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, March 10th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $105.80.

LeMaitre Vascular Price Performance

Shares of LMAT stock traded up $0.79 during trading hours on Tuesday, reaching $112.32. The company's stock had a trading volume of 225,458 shares, compared to its average volume of 204,146. LeMaitre Vascular has a fifty-two week low of $78.35 and a fifty-two week high of $118.01. The firm's 50 day simple moving average is $108.90 and its 200-day simple moving average is $93.99. The company has a quick ratio of 10.95, a current ratio of 12.89 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $2.57 billion, a price-to-earnings ratio of 44.75, a PEG ratio of 3.23 and a beta of 0.60.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 EPS for the quarter, topping analysts' consensus estimates of $0.66 by $0.02. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The company had revenue of $66.55 million during the quarter, compared to analysts' expectations of $66.67 million. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Sell-side analysts forecast that LeMaitre Vascular will post 2.89 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 26th. Investors of record on Thursday, March 12th were given a dividend of $0.25 per share. The ex-dividend date was Thursday, March 12th. This represents a $1.00 dividend on an annualized basis and a yield of 0.9%. This is a positive change from LeMaitre Vascular's previous quarterly dividend of $0.20. LeMaitre Vascular's dividend payout ratio is currently 39.84%.

Insider Activity at LeMaitre Vascular

In other news, insider Trent G. Kamke sold 1,044 shares of the stock in a transaction on Friday, February 27th. The stock was sold at an average price of $110.29, for a total value of $115,142.76. Following the completion of the transaction, the insider directly owned 6,677 shares in the company, valued at approximately $736,406.33. This represents a 13.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David B. Roberts sold 8,464 shares of the firm's stock in a transaction on Friday, February 27th. The shares were sold at an average price of $106.80, for a total value of $903,955.20. Following the sale, the director directly owned 17,979 shares in the company, valued at approximately $1,920,157.20. This trade represents a 32.01% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 215,438 shares of company stock valued at $23,062,911 in the last quarter. Insiders own 7.40% of the company's stock.

Institutional Trading of LeMaitre Vascular

A number of hedge funds have recently made changes to their positions in LMAT. First Trust Advisors LP increased its stake in shares of LeMaitre Vascular by 13.4% in the fourth quarter. First Trust Advisors LP now owns 940,140 shares of the medical instruments supplier's stock valued at $76,245,000 after buying an additional 111,193 shares during the period. State Street Corp boosted its position in LeMaitre Vascular by 0.8% during the 4th quarter. State Street Corp now owns 806,993 shares of the medical instruments supplier's stock worth $65,447,000 after buying an additional 6,130 shares during the period. Geode Capital Management LLC grew its holdings in LeMaitre Vascular by 20.1% during the 4th quarter. Geode Capital Management LLC now owns 633,089 shares of the medical instruments supplier's stock worth $51,351,000 after acquiring an additional 105,921 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in LeMaitre Vascular by 2.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 475,845 shares of the medical instruments supplier's stock worth $38,594,000 after acquiring an additional 13,166 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in LeMaitre Vascular by 144.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 391,254 shares of the medical instruments supplier's stock valued at $31,731,000 after acquiring an additional 231,157 shares during the period. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company's offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre's product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.